Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:49 AM ET 8-K
Financial Results Sagimet Biosciences Inc. SGMT

Sagimet Biosciences Financial Results

Sagimet Biosciences reported third quarter 2026 financial results and provided a corporate update on its Phase 3 AURORA clinical trial for denifanstat in moderate to severe acne. The company highlighted a pro forma cash position of $356 million following a $115 million equity financing in October, which is expected to fund operations through mid-2029.

“Building on the positive Phase 3 results from our license partner Ascletis, we have initiated our pivotal U.S. AURORA Phase 3 clinical trial. With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA.”

David Happel, Chief Executive Officer
7:48 AM ET 8-K
Financial Results ERock, Inc. EROC

ERock Financial Results

ERock reported its first profitable quarter as a public company for Q3 2026, with revenue growing nearly 4x quarter-over-quarter to $152.8 million. The company achieved positive net income of $8.9 million and reaffirmed its full-year 2026 revenue guidance of $435 million to $465 million.

Term
Q3 2026

“We executed well in the third quarter, with record production and deliveries that drove record quarterly revenue and profitability. We began construction at the El Paso Electric facility for Meta, and that project remains on track for completion in mid-2027. We are expanding our manufacturing capacity by 900 MW per year with a new facility in Houston (Atlas). When complete, our total capacity is expected to reach 2.1 GW per year to serve the strong demand for our product. Since the end of the quarter, we added new bookings of more than $300 million, setting a new backlog record and providing revenue and margin visibility into 2028. Our differentiated product and service offerings continue to resonate with customers, and we remain focused on disciplined expansion to meet their needs.”

John Carrington, Chief Executive Officer of ERock

“The third quarter marked an inflection point with revenue growing nearly 4x quarter-over-quarter, driving our first profitable quarter as a public company. We reported $8.9 million of net income and $12.6 million of Adjusted EBITDA. This reflected an improvement of $76.6 million of net income and $26.6 million of Adjusted EBITDA, demonstrating the operating leverage embedded in our business. We expect continued revenue and profitability growth in the fourth quarter and are reaffirming our 2026 guidance. Our robust balance sheet and strong liquidity, coupled with our backlog and unique products and services, give us confidence to expand our manufacturing capacity to meet strong customer demand.”

Ian Blakely, Chief Financial Officer of ERock
7:47 AM ET Form 4
Insider Buying Audiocodes Ltd AUDC

Audiocodes President and CEO Shabtai Adlersberg Buys $143K of Stock

Shabtai Adlersberg, President and CEO, bought 17,000 shares of Audiocodes Ltd at $8.38 to $8.67 a share (average $8.44) in 3 transactions, worth $143K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 4,985,192 (+0.0%).

Value
$143K
Shares
17,000
Average price
$8.44
Role
President and CEO
Holding change
+0.0%
Trade date
Nov 9, 2026 to Nov 11, 2026
7:47 AM ET 10-Q
Financial Results Go Go Buyers, Inc.

Go Go Buyers Q3 2026 Results: Net Loss of $11.7K, Loss Narrows

Go Go Buyers, Inc. reported zero revenue for the nine months ended September 30, 2026, compared to $43,724 in the prior year period. The company incurred a net loss of $56,080 for the first nine months of 2026 and expressed substantial doubt about its ability to continue as a going concern due to a lack of stabilized revenue.

Key figure
Net loss $11.7K
7:46 AM ET 10-Q
Financial Results DPC Holdings PLC DPC ▶ Call

DPC Holdings Q3 2026 Results: Turns Profitable, Net Income $31.8M

DPC Holdings PLC reported a significant revenue increase to $308.1 million for the quarter ended September 27, 2026, and achieved a net income of $31.8 million compared to a net loss in the prior year period. The company successfully completed an initial public offering during the nine-month period, resulting in a substantial improvement in its equity position and a reduction in total liabilities from $1,859.0 million to $529.5 million.

Key figure
Net income $31.8M
7:46 AM ET 8-K
Court & Legal Update Lamb Weston Holdings, Inc. LW

Lamb Weston Holdings Court & Legal Update

Lamb Weston, Inc., a subsidiary of Lamb Weston Holdings, Inc., entered into a $25 million settlement agreement to resolve a putative class action lawsuit regarding groundwater nitrate levels in Oregon. The settlement fund will provide property enhancements and water filtration systems for residents, with payment expected in the second half of fiscal year 2027 subject to court approval.

Counterparty
Private plaintiffs in the U.S. District Court for the District of Oregon
7:45 AM ET 10-Q
Financial Results Latch, Inc. LTCH

Latch Q3 2026 Results: Net Loss of $20.5M, Loss Widens

For the quarter ended September 30, 2026, Latch, Inc. reported total revenue of $14.1 million, a decrease from $17.4 million in the prior year period. The company recognized a significant $13.6 million goodwill impairment charge, contributing to a net loss of $20.5 million compared to a $6.6 million loss in the same quarter of 2025.

Key figure
Net loss $20.5M
7:45 AM ET 8-K
Financial Results Enovix Corp ENVX

Enovix Financial Results

Enovix reported Q3 2026 financial results with revenue of $11.0 million, a 38% increase year-over-year, driven by strong demand in the drone and defense sectors. The company achieved a record non-GAAP gross margin of 34.5% and issued new 2027 revenue guidance of $65 million to $85 million.

“The 100,000-battery order and the first MX1-B01 production order reflect our ability to convert our pipeline into orders. The MX1-B01 has now been sampled by more than 30 industry-leading aerial drone accounts with very positive feedback.”

Steve Bakos, newly appointed Chief Revenue Officer and General Manager of Enovix
7:44 AM ET 8-K
Stock Buyback News Corp NWSA

News Stock Buyback Update

News Corporation provided a daily update on its $1 billion stock repurchase program as required by Australian Securities Exchange (ASX) rules. The company is authorized to repurchase both Class A and Class B common stock in the open market from time to time. The filing includes specific daily transaction notifications for Class A common stock repurchases conducted on the Nasdaq.

7:40 AM ET 10-Q
Financial Results Solo Brands, Inc. SBDS ▶ Call

Solo Brands Q3 2026 Results: Net Loss of $20.8M, Loss Narrows

Solo Brands, Inc. reported a significant increase in cash and cash equivalents to $40.2 million as of September 30, 2026, compared to $20.0 million at year-end 2025. However, total assets decreased from $360.3 million to $322.8 million, driven by lower inventory levels and accounts receivable, while the company continues to manage a substantial long-term debt load of $249.8 million.

Key figure
Net loss $20.8M
7:38 AM ET 8-K
Financial Results Taysha Gene Therapies, Inc. TSHA

Taysha Gene Therapies Financial Results

Taysha Gene Therapies reported third quarter 2026 financial results and provided a corporate update on its TSHA-102 gene therapy program for Rett syndrome. The company completed its BLA-enabling manufacturing campaign and expects to report topline 6-month interim data and receive FDA feedback on its BLA submission pathway in the first half of 2027.

“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102. With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome.”

Sean P. Nolan, Chairman and Chief Executive Officer of Taysha
7:35 AM ET 8-K
Financial Results Falcon's Beyond Global, Inc. FBYD

Falcon's Beyond Global Financial Results

Falcon’s Beyond Global reported Q3 2026 consolidated revenue of $7.3 million, an 80% increase year-over-year, driven by attraction and creative services. The company narrowed its consolidated net loss to $7.7 million and reported a contracted pipeline of $28.0 million for its Attractions and Creative divisions.

Term
Q3 2026

“Our third-quarter results demonstrate continued progress in our growth strategy as we move from building pipeline to executing and delivering major projects. The VAI project announced earlier this year is now underway, bringing together the integrated capabilities of Falcon's Creative and Falcon's Attractions to work across creative design, engineering and attraction delivery.”

Cecil D. Magpuri, Chief Executive Officer of Falcon’s Beyond
7:35 AM ET 8-K
Financial Results Capstone Holding Corp. CAPS

Capstone Holding Financial Results

Capstone Holding Corp. reported Q3 2026 revenue of $20.0 million, a 46% year-over-year increase, and achieved operating income of $0.4 million. The company updated its full-year 2026 revenue guidance to $70 million, citing higher interest rates slowing housing activity, while noting that its organic sales growth continues to outperform the broader market.

Term
Q3 2026

“We grew revenue 46% and generated income from operations in a difficult housing market. Each of our operating businesses has outperformed its respective market this year, with growth accelerating in the third quarter.”

Matthew E. Lipman, Chief Executive Officer
7:35 AM ET 8-K
Financial Results Solo Brands, Inc. SBDS

Solo Brands Financial Results

Solo Brands reported third quarter 2026 net sales of $43.7 million, a 17.6% decrease year-over-year, alongside a net loss of $20.8 million. Despite the revenue decline, the company improved its Adjusted EBITDA margin and generated $6 million in operating cash flow through disciplined cost management and reduced promotional activity.

Term
Q3 2026

“While the third quarter is typically our seasonally smallest sales quarter, we continued to make measurable progress strengthening the business. We improved segment profitability, generated more than $6 million of operating cash flow, and further advanced our transformation strategy through disciplined execution, cost management, and operational efficiency initiatives.”

John Larson, President and Chief Executive Officer

“While revenue performance remains below our expectations, we are encouraged by improving consumer engagement and the strong response to recent product innovation. Products launched over the past year for our Solo Stove segment represented nearly half of our website sales during the quarter, highlighting the strength of our innovation pipeline and the value of our brand portfolio.”

John Larson, President and Chief Executive Officer
7:34 AM ET 8-K
Financial Results Altimmune, Inc. ALT

Altimmune Financial Results

Altimmune reported third quarter 2026 financial results and provided a business update on its pemvidutide clinical programs. The company ended the quarter with $480 million in cash and is progressing its Phase 3 PERFORMA trial in MASH and preparing for an End-of-Phase 2 meeting with the FDA for its AUD program in December 2026.

“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide. Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community.”

Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune

“In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide’s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”

Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
7:33 AM ET Form 4
Insider Selling FIGS, Inc. FIGS

FIGS CFO Sarah Oughtred Sells $1.97M of Stock

Sarah Oughtred, CFO, sold 90,000 shares of FIGS, Inc. at $21.92 a share, worth $1.97M in total on Nov 11, 2026. Shares held after the trade: 954,007 (-8.6%).

Value
$1.97M
Shares
90,000
Price
$21.92
Role
CFO
Holding change
-8.6%
Trade date
Nov 11, 2026
7:33 AM ET 8-K
Financial Results Intuitive Machines, Inc. LUNR

Intuitive Machines Financial Results

Intuitive Machines reported record third-quarter 2026 financial results, achieving revenue of $269 million and positive free cash flow of $33 million. The company ended the quarter with a record backlog of $1.9 billion, driven by significant contract wins including NASA's $10 billion CLPS 2 IDIQ award and the acquisition of Goonhilly Earth Station.

Term
Q3 2026

“In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the state of lunar exploration into a next-generation space prime developing and integrating the technology, infrastructure and services that enable customers to achieve their differentiated missions across space.”

Steve Altemus, CEO

“As we look to turn the corner into 2027, we remain laser focused on IM-3 along with our first Altus-1 lunar satellite, which remains on track for a planned launch in the March/April timeframe. In addition, our emphasis will be to continue to scale execution and accelerate growth. We expect to convert contracted backlog into revenue through repeatable production, operational excellence, and reliable customer delivery.”

Steve Altemus, CEO
7:32 AM ET 8-K
M&A Deal Installed Building Products, Inc. IBP

Installed Building Products Signs $725M M&A Deal with 1981 Holdco, Inc.

Installed Building Products (IBP) acquired Old Dominion Group (ODG), a leading mechanical and industrial insulation installer, for a base purchase price of $725 million. The deal was funded with 60% cash and 40% IBP common stock, establishing a scaled commercial and industrial installation platform with approximately $420 million in combined LTM revenue. The acquisition increases IBP's commercial end-market exposure to approximately 28% of total revenue and is expected to be immediately accretive to adjusted EPS.

Value
$725M
Counterparty
1981 Holdco, Inc. (Old Dominion Group)
7:32 AM ET 8-K
Investor Presentation Kraft Heinz Co KHC

Kraft Heinz Investor Presentation

Kraft Heinz is hosting its 2026 Investor Day to outline a strategic path for sustainable, volume-led profitable growth through 2029. The company expects to return to top- and bottom-line growth in the second half of 2027 and aims for double-digit total shareholder return by 2029 through a self-reinforcing cycle of growth and capital returns.

7:32 AM ET 10-Q
Financial Results Grace Therapeutics, Inc. GRCE

Grace Therapeutics Q2 2026 Results: Net Loss of $2.13M, Loss Widens

Grace Therapeutics reported a net loss of $17.9 million for the six months ended September 30, 2026, primarily driven by a $13.5 million impairment of intangible assets related to GTx-102 and GTx-101. The company strengthened its liquidity through a $9.2 million private placement in August 2026, providing sufficient cash to fund operations for at least 12 months.

Key figure
Net loss $2.13M
7:32 AM ET 10-Q
Financial Results Lumexa Imaging Holdings, Inc. LMRI

Lumexa Imaging Holdings Q3 2026 Results: Turns Profitable, Net Income $7.18M

Lumexa Imaging Holdings reported a net income of $7.2 million for the third quarter of 2026, a significant recovery from a $3.5 million loss in the prior year period. Total revenues grew to $272.0 million, driven by increases in net patient service and management fee revenue, while the company maintained a strong cash position of $90.0 million.

Key figure
Net income $7.18M
7:31 AM ET 10-Q
Financial Results Btcs Inc. BTCS

Btcs Q3 2026 Results: Net Income $54.5M, Down 16.9% YoY

For the nine months ended September 30, 2026, BTCS Inc. reported total revenues of $8.7 million and a net loss of $49.5 million, primarily driven by $30.6 million in realized losses on digital asset transactions and $11.2 million in impairment losses. This represents a significant downturn from the $52.2 million net income reported in the prior year period, despite a substantial increase in DeFi-related revenue.

Key figure
Net income $54.5M · -16.9% YoY
7:31 AM ET 8-K
Licensing Deal Vor Biopharma Inc. VOR

Vor Biopharma Licensing Deal with RemeGen Co., Ltd. Worth $10M

Vor Biopharma expanded its existing partnership with RemeGen by entering into an amended and restated license agreement to add RC298, a next-generation dual BAFF/APRIL inhibitor, to its exclusive development and commercialization rights outside of Greater China. Vor Bio will pay an upfront cash payment of $10 million and issue a pre-funded warrant for 2.3 million shares, with RemeGen eligible for up to $630 million in development and regulatory milestones plus tiered royalties.

Value
$10M
Counterparty
RemeGen Co., Ltd.
7:31 AM ET 10-Q
Financial Results Taysha Gene Therapies, Inc. TSHA

Taysha Gene Therapies Q3 2026 Results: Net Loss of $39.1M, Loss Widens

Taysha Gene Therapies reported a net loss of $128.2 million for the nine months ended September 30, 2026, compared to $81.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through an underwritten public offering that raised approximately $215.7 million, ending the period with $422.8 million in cash and cash equivalents.

Key figure
Net loss $39.1M
7:31 AM ET 10-Q
Financial Results Falcon's Beyond Global, Inc. FBYD

Falcon's Beyond Global Q3 2026 Results: Net Loss of $3.86M, Loss Narrows

Falcon's Beyond Global, Inc. reported that as of November 12, 2026, it had 49,226,743 Class A and 72,169,750 Class B shares outstanding. The company disclosed substantial doubt about its ability to continue as a going concern due to current liquidity resources and noted material adverse impacts from impairments of intangible assets and equity method investments.

Key figure
Net loss $3.86M
7:31 AM ET 10-Q
Financial Results Capstone Holding Corp. CAPS

Capstone Holding Q3 2026 Results: Net Loss of $632K, Loss Narrows

Capstone Holding Corp. reported net sales of $54.1 million for the nine months ended September 30, 2026, a significant increase from $34.4 million in the prior year. Despite higher sales, the company incurred a net loss of $3.9 million for the period, though this was an improvement over the $4.4 million net loss reported in 2025.

Key figure
Net loss $632K
7:31 AM ET 10-Q
Financial Results Sagimet Biosciences Inc. SGMT

Sagimet Biosciences Q3 2026 Results: Net Loss of $19.1M, Loss Widens

Sagimet Biosciences Inc. reported a significant increase in total assets to $282.1 million as of September 30, 2026, up from $116.5 million at the end of 2025, primarily driven by growth in cash and marketable securities. The company is advancing its lead drug candidate, denifanstat, through clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Current liabilities also increased to $38.0 million, including a $27.5 million liability for proceeds received for equity not yet issued.

Key figure
Net loss $19.1M
7:31 AM ET 8-K
Financial Results Yesway, Inc. YSWY

Yesway Financial Results

Yesway, Inc. reported third quarter 2026 financial results, featuring a net income increase to $24.8 million and an 8.6% rise in Adjusted EBITDA to $59.6 million. The company achieved same-store inside merchandise sales growth of 1.9% and expanded its footprint by opening two new stores, including its first location in Arizona.

“We delivered another exceptional quarter, building on our strong performance in the first half of 2026. We continued to grow inside merchandise sales and fuel gallons, expand our market share, and deliver strong profitability against a challenging consumer environment.”

Thomas N. Trkla, Chairman, President and Chief Executive Officer

“We are proud of what our team has accomplished and excited for what is ahead for Yesway as we continue to advance our three growth priorities – new store development, initiatives that strengthen our existing operations, and selective acquisitions – and drive long-term value for all our stakeholders.”

Thomas N. Trkla, Chairman, President and Chief Executive Officer
7:31 AM ET 8-K
Investor Presentation Arbutus Biopharma Corp ABUS

Arbutus Biopharma Investor Presentation

Arbutus Biopharma Corporation has posted an updated corporate presentation for Q4 2026 to its website and filed it with the SEC. The presentation outlines the company's strategic focus on developing a functional cure for chronic hepatitis B virus (HBV), including the clinical development of its lead candidate imdusiran. The filing serves as a routine update for investors regarding the company's pipeline, clinical trial designs, and future prospects.

7:26 AM ET 10-Q
Financial Results Howard Hughes Corp HHC

Howard Hughes Q3 2026 Results: Net Loss of $51.1M

For the nine months ended September 30, 2026, Howard Hughes Corp reported total revenues of $1.52 billion, a significant increase from $850.4 million in 2025, primarily driven by a surge in condominium rights and unit sales. Net income attributable to the company rose to $144.4 million for the nine-month period, despite a net loss of $49.9 million in the third quarter due to a $105.4 million loss on the sale of Municipal Utility District receivables.

Key figure
Net loss $51.1M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.